A Review on Herbal Drugs used in the Management of Anxiety Disorders

What is anxiety?

Anxiety is a multifaceted neuropsychological condition marked by excessive worry, ongoing fear, and elevated emotional and physical responses to stress or expected negative outcomes.[1] It entails disruptions in cognitive, behavioral, autonomic, and neuroendocrine systems, potentially severely affecting a person’s daily routines and general quality of life.[2] In clinical terms, it manifests through symptoms like restlessness, irritability, difficulty concentrating, muscle tension, rapid heartbeat, sweating, trembling, palpitations, digestive issues, and sleep problems.[3] Neurobiological changes involving neurotransmitters such as gamma-aminobutyric acid (GABA), serotonin, dopamine, and norepinephrine are believed to be central to the development of anxiety disorders.[4] If left unchecked, anxiety can adversely impact emotional balance, social interactions, job performance, and overall psychological health.[5]

Classification of Anxiety Disorders

1. Generalized Anxiety Disorder (GAD)

Generalized Anxiety Disorder is a long-term anxiety condition marked by ongoing, excessive, and difficult-to-control worry about routine daily activities and events.[6] This anxiety is typically out of proportion to the actual circumstances and lasts for at least six months.[7] Typical symptoms include restlessness, tiredness, difficulty concentrating, irritability, muscle tension, and trouble sleeping.[8] The disorder substantially impacts social, work, and mental functioning and is often linked with depression and other anxiety-related conditions.[9]

2. Panic Disorder (PD)

Panic Disorder is marked by recurring, unexpected panic attacks, which trigger intense fear and physical symptoms of arousal.[10] These attacks include sudden episodes of chest pain, rapid heartbeat, dizziness, sweating, shaking, breathlessness, and a fear of death or losing control.[11] Many patients experience anticipatory anxiety and avoid certain situations out of fear of future attacks.[12] The condition frequently occurs alongside agoraphobia and significantly disrupts daily life.[13]

3. Social Phobia (Social Anxiety Disorder)

Social Anxiety Disorder is characterized by an intense and enduring fear of social or performance settings where one might face criticism, embarrassment, or negative judgment.[14] Being in such situations can trigger significant anxiety symptoms, including trembling, blushing, rapid heartbeat, and sweating.[15] The condition often leads to avoidance, social withdrawal, decreased work performance, and strained personal relationships.[16] It typically emerges during adolescence and may persist long-term if not addressed.[17]

4. Obsessive-Compulsive Disorder (OCD)

Obsessive-Compulsive Disorder is marked by recurring obsessions and compulsions.[18] Obsessions are unwanted, anxiety-inducing thoughts, images, or urges, while compulsions are repetitive actions carried out to ease anxiety or avoid perceived danger.[19] Typical obsessions include fears of contamination, a need for symmetry, and unwanted aggressive thoughts, while common compulsions involve over-washing hands, checking things repeatedly, counting, and engaging in ritualistic behaviors.[20] The condition can significantly disrupt personal, social, and work-related functioning.[21]

5. Post-Traumatic Stress Disorder (PTSD)

Post-Traumatic Stress Disorder arises after experiencing traumatic or life-threatening events, including violence, war, accidents, or natural disasters.[22] It is marked by intrusive memories, nightmares, flashbacks, emotional detachment, avoidance of trauma-related triggers, hypervigilance, and sleep problems.[23] PTSD is linked to significant psychological suffering, reduced quality of life, and a high prevalence of co-occurring psychiatric conditions, especially depression and other anxiety disorders.[24]

Risk Factors of Anxiety

Anxiety disorders are complex psychiatric conditions resulting from the interplay of biological, psychological, environmental, and social factors.[25] These elements affect emotional regulation, neurochemical processes, stress reactivity, and behavioral adjustment, thereby heightening vulnerability to anxiety disorders.[26]

1. Biological Factors

Genetic predisposition is widely regarded as a key factor in the onset of anxiety disorders.[27] People with a family history of anxiety, depression, or other mental health conditions are at substantially greater risk of developing pathological anxiety.[28] Imbalances in neurochemical systems, particularly those involving gamma-aminobutyric acid (GABA), serotonin, dopamine, and norepinephrine can disrupt neuronal communication and lead to heightened autonomic activity.[29] Additionally, chronic illnesses, hormonal imbalances, neurological conditions, sleep disruptions, and age-related physiological shifts may further heighten susceptibility to anxiety symptoms.[30]

2. Psychological Factors

Psychological vulnerability is a key factor in the development of anxiety.[31] Persistent negative thinking, poor coping strategies, an overblown sense of fear, emotional instability, and maladaptive behaviors are closely linked to anxiety disorders.[32] Prior psychiatric diagnoses, unprocessed emotional trauma, long-term psychological stress, and negative childhood experiences can greatly increase the risk of anxiety-related conditions.[33] Personality traits including neuroticism, hypersensitivity, low self-esteem, and poor stress resilience are also regarded as major psychological risk factors.[34]

3. Social and Environmental Factors

Environmental and psychosocial stressors play a major role in triggering and worsening anxiety disorders.[35] Commonly linked to increased psychological distress are social isolation, financial hardship, job-related stress, academic pressure, interpersonal conflicts, and lack of social support.[36] Experiencing traumatic events such as violence, abuse, war, accidents, natural disasters, or emotional loss can substantially raise the risk of severe anxiety disorders, especially Post-Traumatic Stress Disorder (PTSD).[37] Additionally, lifestyle factors like smoking, alcohol use, substance abuse, and physical inactivity may worsen anxiety symptoms and impair daily functioning.[38]

4. Demographic Factors

Several demographic factors are linked to a higher prevalence of anxiety disorders.[39] Epidemiological research shows that anxiety disorders are more frequently seen in women, older adults, and individuals with chronic medical conditions or disabilities.[40] Additional contributors to the onset and continuation of anxiety disorders may include low socioeconomic status, cognitive impairment, decreased social engagement, and diminished quality of life.[41]

Epidemiology of Anxiety

Anxiety disorders are among the most common psychiatric conditions globally and pose a major public health challenge because of their long-term nature, early onset, and considerable psychosocial impact.[42] Research across diverse populations reveals that anxiety disorders often occur alongside mood disorders, substance use disorders, and other mental health conditions, which worsens functional impairment and lowers quality of life.[43]

Anxiety disorders typically begin in childhood, adolescence, or early adulthood, with a particularly elevated risk between the ages of 10 and 35.[44] Specific phobias and social anxiety disorder usually emerge during childhood or adolescence, while generalized anxiety disorder and panic disorder may appear later in adulthood.[45] Without proper treatment, many anxiety disorders tend to be persistent and recurrent.[46] Epidemiological data consistently show that anxiety disorders are more common in women than in men.[47] Higher rates are also linked to individuals who are widowed, divorced, socially isolated, or economically disadvantaged.[48] Differences in prevalence across countries and cultures may stem from variations in diagnostic standards, environmental stressors, socioeconomic factors, and access to healthcare.[49]

Comorbidity is a key feature of anxiety disorders. Many individuals affected by these conditions also suffer from co-occurring psychiatric disorders such as depression, obsessive-compulsive disorder, post-traumatic stress disorder, and substance dependence.[50] The presence of multiple psychiatric conditions markedly worsens disease severity, increases healthcare demands, and impairs occupational functioning.[51]

Genetic vulnerability, environmental stressors, traumatic events, maladaptive coping mechanisms, and neurobiological changes are regarded as key epidemiological factors linked to anxiety disorders.[52] Given the rising prevalence and socioeconomic consequences of anxiety disorders, early detection, prevention, and effective treatment remain critical priorities in contemporary mental health care systems.[53]

Pathophysiology of Anxiety

The development of anxiety disorders stems from intricate interactions among neurobiological, genetic, neurochemical, endocrine, and environmental factors that together shape emotional regulation and the body’s response to stress.[54] Central to the onset of these disorders is the malfunction of specific brain areas that govern fear processing and behavioral control.[55] The amygdala is among the key neural structures implicated in the emergence of anxiety.[56] Overactivity in the amygdala can lead to heightened fear perception, emotional sensitivity, and amplified reactions to stressful or threatening situations.[57] Dysfunction in regions such as the hippocampus, orbitofrontal cortex, insular cortex, and prefrontal cortex may further compromise emotional control, memory consolidation, and the ability to respond adaptively to challenges.[58]

Imbalances in neurotransmitters are a major contributor to anxiety disorders.[59] A decrease in the inhibitory effects of gamma-aminobutyric acid (GABA) is linked to increased neuronal excitability and heightened autonomic activity.[60] Disruptions in serotonergic, dopaminergic, and noradrenergic signaling may also contribute to ongoing anxiety, panic episodes, mood fluctuations, and reduced resilience to stress.[61]

Another critical mechanism involves dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, which is often implicated in anxiety disorders.[62] Persistent psychological stress can trigger excessive cortisol release, leading to prolonged autonomic arousal, sleep disruption, emotional volatility, and diminished cognitive performance.[63]

Genetic predisposition and environmental factors together play a role in the development of anxiety.[64] People who inherit traits such as behavioral inhibition, an anxious temperament, or have a family history of psychiatric conditions are more likely to develop anxiety disorders.[65] Prolonged stress, childhood trauma, social hardship, neglect, or exposure to traumatic events can modify brain circuitry and neuroplasticity, raising the risk for enduring anxiety symptoms.[66]

New neuroscientific research suggests that disrupted communication between the amygdala, hippocampus, and prefrontal cortex may lead to difficulties in extinguishing fear and heightened anticipatory anxiety.[67] Additionally, neuroinflammation, reduced synaptic plasticity, and problems in emotional learning processes have been linked to the progression of anxiety disorders.[68]

Clinical manifestation of Anxiety Disorders

Anxiety disorders involve a wide range of psychological, cognitive, behavioral, and physical symptoms that substantially disrupt daily activities and overall quality of life.[69] The intensity and nature of symptoms can differ based on the particular type of anxiety disorder, how long the illness has lasted, individual susceptibility, and related psychosocial stressors.[70] Ongoing anxiety symptoms frequently hinder work performance, academic engagement, personal relationships, and social participation.[71]

1. Psychological Manifestations

Psychological symptoms are among the most noticeable clinical indicators of anxiety disorders.[72] People often report ongoing, excessive worry, fear, apprehension, irritability, nervousness, emotional discomfort, and a persistent feeling of imminent danger.[73] Increased vigilance, restlessness, and difficulty managing anxious thoughts are commonly seen.[74] Many patients also describe a sense of helplessness, emotional volatility, and an overestimation of the likelihood of negative events.[75]

2. Cognitive Symptoms

Cognitive dysfunction is commonly linked to anxiety disorders and can manifest as difficulty concentrating, short attention spans, racing thoughts, indecisiveness, memory problems, and a skewed perception of threat.[76] Patients frequently display catastrophic thinking, an exaggerated sense of danger, and ongoing negative predictions about future events.[77] These unhelpful cognitive patterns intensify anxiety reactions and fuel long-term psychological suffering.[78]

3. Behavioral Manifestations

Common behavioral signs include avoiding anxiety-triggering situations, withdrawing socially, seeking constant reassurance, and cutting back on regular activities.[79] People with social anxiety disorder or specific phobias may deliberately steer clear of social contact, public settings, or the objects or scenarios they fear.[80] Repeated safety behaviors, meant to lessen perceived danger, may briefly ease anxiety but often perpetuate and intensify symptoms in the long run.[81]

4. Physical and Bodily Symptoms

Anxiety disorders are often linked to autonomic and somatic symptoms caused by overactivity of the sympathetic nervous system.[82] Typical physical signs include palpitations, rapid heartbeat, sweating, shaking, chest pressure, breathlessness, lightheadedness, nausea, dry mouth, digestive issues, headaches, muscle tightness, exhaustion, and disrupted sleep.[83] In more severe instances, panic attacks may arise, marked by abrupt, overwhelming fear along with cardiovascular and respiratory symptoms.[84] These physical symptoms can resemble serious medical conditions and may lead to higher healthcare use and diagnostic uncertainty.[85]

5. Disorder-Specific Manifestations

Each anxiety disorder exhibits unique clinical features.[86] Generalized Anxiety Disorder is defined by ongoing, uncontrollable worry, restlessness, irritability, and muscle tension.[87] Panic Disorder involves frequent, unexpected panic attacks and a persistent dread of future episodes.[88] Social Anxiety Disorder features an overwhelming fear of being judged, embarrassed, or humiliated in social settings, often leading to avoidance.[89] Specific Phobias entail disproportionate and irrational fear of certain objects, animals, activities, or environments.[90] Post-Traumatic Stress Disorder is linked to recurring memories and nightmares, emotional detachment, heightened alertness, and avoidance of reminders of the traumatic event.[91]

6. Functional Impairment

Persistent anxiety symptoms can severely disrupt social, occupational, academic, and personal functioning.[92] If left untreated, anxiety disorders may lead to social isolation, decreased productivity, diminished quality of life, sleep problems, and a higher likelihood of developing other mental health conditions, including depression and substance use disorders.[93] Identifying these symptoms early is crucial for proper diagnosis, prompt treatment, and effective management of anxiety disorders.[94]

Diagnosis of Anxiety Disorders

Diagnosing anxiety disorders requires a thorough clinical evaluation that considers psychological symptoms, behavioral tendencies, physical signs, and the extent to which the individual’s daily functioning is affected.[95] Precise diagnosis is crucial for distinguishing anxiety disorders from typical stress reactions, medical conditions, and other mental health disorders, which in turn supports effective treatment and care.[96]

1. Clinical Evaluation

Clinical evaluation continues to be the primary method for diagnosing anxiety disorders.[97] A comprehensive psychiatric history is gathered to evaluate the onset, duration, frequency, intensity, and course of anxiety symptoms.[98] Clinicians also examine related psychological symptoms, including excessive fear, chronic worry, irritability, restlessness, panic attacks, sleep issues, and avoidance behaviors.[99] Evaluating how anxiety affects occupational, academic, and social functioning is essential for understanding its overall impact on daily life.[100]

2. Diagnostic Criteria

The diagnosis of anxiety disorders mainly relies on standardized criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and the International Classification of Diseases (ICD-11).[101] Under DSM-5, anxiety symptoms must be ongoing, excessive, and mismatched with the situation, leading to noticeable distress or functional impairment.[102] Generally, symptoms need to last at least six months to confirm a diagnosis for most anxiety disorders.[103]

3. Mental Status Examination

The mental status examination is crucial for detecting the specific psychological and cognitive abnormalities linked to anxiety disorders.[104] During clinical evaluation, patients may display anxious mood, heightened worry, difficulty concentrating, hypervigilance, rapid speech, restlessness, and physical signs of anxiety.[105] Assessing thought content, emotional regulation, perception, insight, and judgment helps distinguish anxiety disorders from psychotic, depressive, and personality disorders.[106]

4. Tools for Psychological Assessment

A range of standardized screening and assessment tools are employed to evaluate the severity and characteristics of anxiety symptoms.[107] Frequently used instruments include the Hamilton Anxiety Rating Scale (HAM-A), Generalized Anxiety Disorder-7 (GAD-7), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale (HADS).[108] These measures help quantify symptoms, guide treatment planning, and track progress over time.[109]

5. Physical Examination and Laboratory Investigations

A thorough physical exam and laboratory testing are crucial for ruling out medical conditions that can resemble anxiety symptoms.[110] Conditions like hyperthyroidism, heart disease, respiratory issues, neurological disorders, hormonal imbalances, and substance-related illnesses may produce symptoms indistinguishable from anxiety disorders.[111] Laboratory tests might involve thyroid function assessments, complete blood counts, blood glucose levels, toxicology screens, and other appropriate diagnostic measures based on the patient’s clinical presentation.[112]

6. Differential Diagnosis

Differential diagnosis is crucial because anxiety symptoms often mimic those of other psychiatric and medical conditions.[113] Common conditions evaluated during this process include depressive disorders, bipolar disorder, schizophrenia, obsessive-compulsive disorder, substance use disorders, panic attacks triggered by medical illnesses, and personality disorders.[114] A thorough assessment is essential to correctly identify the root cause and avoid misdirected treatment strategies.[115]

7. Importance of Early Diagnosis

Identifying anxiety disorders early is crucial to avoid long-term psychological damage and to enhance treatment effectiveness.[116] If left undetected, symptoms may intensify, leading to social difficulties, diminished quality of life, and a higher likelihood of developing additional mental or physical health conditions.[117] Thus, a thorough diagnostic evaluation is vital for enabling prompt intervention, personalized treatment strategies, and sustained management of anxiety disorders.[118]

Herbal Drugs in Anxiety Management

Herbal remedies have long been employed to address anxiety, insomnia, nervousness, and other stress-related conditions. These medicinal plants include bioactive compounds like flavonoids, alkaloids, terpenoids, and essential oils, which have anxiolytic and sedative effects.

1. Hops (Humulus lupulus)

Hops are commonly employed in traditional medicine to address sleep issues and anxiety. The plant includes bitter acids, flavonoids, and essential oils that contribute to its sedative effects. Research indicates that hops could enhance sleep quality and soothe the nervous system. Hops are frequently paired with valerian in herbal remedies aimed at managing insomnia [119-121].

2. Bay Laurel (Laurus nobilis)

Laurus nobilis contains essential oils that are rich in eugenol and cineole. The herb has anti-inflammatory pain-relieving, antioxidant, and soothing properties. Bay leaves are used in traditional medicine to help relieve stress and nervous tension [122-125].

3. Lavender (Lavandula angustifolia)

Lavender is among the most widely researched medicinal plants for managing anxiety. Its essential oil includes linalool and linalyl acetate, known for their calming and sedative properties. Clinical studies have shown that lavender aromatherapy and oral formulations help reduce anxiety symptoms and enhance sleep quality [126-133].

4. Common Mallow (Malva sylvestris)

Malva sylvestris contains a high concentration of flavonoids, anthocyanins, and phenolic compounds. The plant exhibits antioxidant and anti-inflammatory properties that could help protect the nervous system and reduce stress [134-140].

5. Chamomile (Matricaria chamomilla)

Chamomile has been traditionally used as a soothing herbal tea for a long time. It includes flavonoids and terpenoids that have sedative and anxiolytic properties. Chamomile is frequently used to address anxiety, insomnia, stress, and gastrointestinal issues linked to nervousness [141-150].

6. Lemon Balm (Melissa officinalis)

Melissa officinalis has soothing and anxiety-reducing effects. The plant includes citral, rosmarinic acid, and flavonoids, which are responsible for its neuroprotective and sedative effects. Studies involving experimental models have demonstrated a reduction in anxiety-like behavior following the administration of lemon balm extracts [151-157].

7. Basil (Ocimum basilicum)

Basil is a fragrant medicinal herb that contains linalool, eugenol, and methyl chavicol. It exhibits antioxidant, anti-inflammatory, sedative, and hypnotic effects. Extracts from basil have demonstrated positive effects on reducing stress and improving sleep [158-164].

8. Rosemary (Rosmarinus officinalis)

Rosemary includes bioactive compounds like rosmarinic acid and essential oils, which show antioxidant and neuroprotective effects. Aromatherapy and rosemary tea have been linked to lower anxiety, better mood, and improved cognitive function [165-173].

9. Linden (Tilia cordata / Tilia americana)

Tilia species have traditionally been used to make calming herbal teas. The flowers include flavonoids and volatile compounds that have anxiolytic and sedative effects. Research suggests positive outcomes for nervous disorders and insomnia [174-180].

10. Valerian (Valeriana officinalis)

Valerian is one of the most frequently used herbal remedies for insomnia and anxiety. The plant includes valerenic acid, alkaloids, and valepotriates, which exert effects on the GABAergic system to induce calming and sedative properties. Multiple clinical studies and meta-analyses have assessed valerian for its effectiveness as a sleep aid and anxiolytic [181-190].

Advantages and Limitations of Herbal Drugs

Herbal medicines are commonly employed in treating anxiety disorders because they are derived from natural sources, enjoy cultural acceptance, and generally cause fewer side effects. Herbs like valerian, lavender, chamomile, lemon balm, and rosemary have demonstrated encouraging anxiolytic and sedative effects in both traditional healing practices and contemporary scientific research. Nevertheless, while herbal medicines have therapeutic potential, they also have certain limitations that hinder their widespread clinical use.

Benefits of Herbal Medicines

1. Natural Origin

Herbal medicines come from natural plant sources and are commonly seen as safer options compared to synthetic drugs. Their natural composition enhances patient acceptance and promotes long-term use [191].

2. Less Side Effects

In comparison to traditional anxiolytic drugs like benzodiazepines, many herbal remedies tend to cause fewer side effects, such as a lower likelihood of dependence, tolerance, and withdrawal symptoms [192].

3. Cost-Effectiveness

Most medicinal plants are cheap and readily accessible, particularly in developing countries. This renders herbal therapy a cost-effective option for the long-term management of anxiety disorders [193].

4. Multiple Pharmacological Effects

Many herbal drugs have several therapeutic effects, including anxiolytic, sedative, antioxidant, anti-inflammatory, and neuroprotective actions. These combined effects may enhance overall mental health and wellbeing [194].

5. Cultural and Traditional Acceptance

Medicinal plants have been used for centuries in traditional healing systems like Ayurveda, Unani, and Traditional Chinese Medicine. Their historical use enhances public trust and acceptance across various populations [195].

6. Improved Patient Adherence

Herbal remedies including teas, oils, capsules, and aromatherapy products are typically well accepted and favored by patients pursuing natural therapies for anxiety and sleep issues [196].

Constraints of Herbal Medicines

1. Lack of Standardization

A significant drawback of herbal medicines is the inconsistency in their chemical makeup, which stems from variations in plant species, growing conditions, harvesting practices, and extraction methods. This impacts the consistency and effectiveness of herbal products [197].

2. Lack of Adequate Clinical Evidence

While numerous medicinal plants show encouraging outcomes in experimental research, large-scale clinical trials remain scarce for many herbal remedies employed in managing anxiety [198].

3. Gradual Onset of Action

Herbal medicines typically need extended use before noticeable therapeutic benefits appear, in contrast to synthetic anxiolytic drugs, which can take effect quickly [199].

4. Potential for Drug Interactions

Some herbal remedies can interfere with prescription medications and change how they work in the body. These interactions may result in decreased effectiveness or harmful effects [200].

5. Problems with Quality Control

Contamination, tampering, and inadequate storage can compromise the safety and efficacy of herbal products. In some regions, the absence of stringent regulatory oversight continues to be a major concern [201].

6. Limited Awareness and Scientific Validation

Many healthcare professionals and patients do not have sufficient understanding of the correct dosage, safety, and mechanisms of action of herbal medicines. Many traditional claims still need scientific validation [202].

Future Scope

The application of herbal drugs in managing anxiety has attracted considerable attention, driven by growing interest in natural and safer treatment options. While many medicinal plants have shown encouraging anxiolytic and sedative properties, additional scientific investigation is needed to confirm their effectiveness, safety, and suitability for clinical use [203].

Future research should concentrate on isolating and identifying the active phytochemical compounds that contribute to anxiolytic effects. Advanced analytical and pharmacological methods could aid in elucidating the precise mechanisms by which herbal compounds affect the central nervous system [204].

Large-scale randomized clinical trials are necessary to confirm the therapeutic potential of herbal medicines for anxiety disorders. These studies may offer scientific evidence on the ideal dosage, treatment duration, long-term safety, and effectiveness compared to traditional anxiolytic medications [205].

Another key area for future development is the standardization of herbal formulations. Differences in cultivation conditions, harvesting, processing, and extraction techniques frequently influence the quality and uniformity of herbal products. Implementing standardized manufacturing processes and quality control protocols could enhance reliability and therapeutic efficacy [206].

Advanced drug delivery methods, including nanoformulations, encapsulation, and controlled-release systems, can improve the bioavailability and stability of herbal compounds. These advanced technologies may enhance the clinical application of herbal medicines in psychiatric disorders [207].

Future studies should also explore potential herb-drug interactions and toxicological profiles to guarantee safe use in combination with standard medications. Effective pharmacovigilance systems and regulatory structures are essential to safely incorporate herbal therapies into contemporary healthcare systems [208].

Moreover, raising public awareness and incorporating evidence-based herbal medicine into healthcare education could encourage thoughtful and well-informed use of medicinal plants for managing anxiety.

CONCLUSION

Anxiety disorders are among the most prevalent mental health conditions globally and have a major impact on a person’s emotional, psychological, and social well-being. Though benzodiazepines and antidepressants are commonly prescribed for treatment, long-term use can result in side effects such as dependence, drowsiness, tolerance, and withdrawal symptoms. Due to these limitations, herbal medicines are receiving growing attention as a safer and more natural way to manage anxiety.

Several medicinal plants including Valeriana officinalis, Lavandula angustifolia, Melissa officinalis, Matricaria chamomilla, and Rosmarinus officinalis have demonstrated promising anxiolytic, sedative, antioxidant, and neuroprotective effects, primarily attributed to their bioactive constituents such as flavonoids, alkaloids, terpenoids, and essential oils. Research and clinical trials indicate that these herbal remedies might help alleviate anxiety, enhance sleep, and encourage relaxation while causing fewer side effects.

Overall, herbal drugs show considerable promise in treating anxiety disorders and could function as effective complementary treatments. Nevertheless, additional clinical studies, standardization, and safety assessments are required to guarantee their effectiveness, quality, and safe use in today’s healthcare systems.

REFERENCES

1. Diagnostic and Statistical Manual of Mental Disorders American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; American Psychiatric Publishing: Arlington, VA, USA, 2013.
2. World Health Organization. International Classification of Diseases 11th Revision (ICD-11); WHO: Geneva, Switzerland, 2019.
3. Baldwin, D.S.; Waldman, S.; Allgulander, C. Evidence-based pharmacological treatment of generalized anxiety disorder. Int. J. Neuropsychopharmacol. 2011, 14, 697–710.
4. Nuss, P. Anxiety disorders and GABA neurotransmission: A disturbance of modulation. Neuropsychiatr. Dis. Treat. 2015, 11, 165–175.
5. Bandelow, B.; Michaelis, S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin. Neurosci. 2015, 17, 327–335.
6. Stein, D.J.; Sareen, J. Generalized Anxiety Disorder. N. Engl. J. Med. 2015, 373, 2059–2068.
7. Locke, A.B.; Kirst, N.; Shultz, C.G. Diagnosis and management of generalized anxiety disorder and panic disorder in adults. Am. Fam. Physician 2015, 91, 617–624.
8. Craske, M.G.; Stein, M.B. Anxiety.Lancet 2016, 388, 3048–3059.
9. Kessler, R.C.; Berglund, P.; Demler, O.; Jin, R.; Merikangas, K.R.; Walters, E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders. Arch. Gen. Psychiatry 2005, 62, 593–602.
10. Roy-Byrne, P.P.; Craske, M.G.; Stein, M.B. Panic disorder. Lancet 2006, 368, 1023–1032.
11. Barlow, D.H. Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic, 2nd ed.; Guilford Press: New York, NY, USA, 2002.
12. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Panic Disorder; APA: Washington, DC, USA, 2009.
13. Stein, M.B.; Stein, D.J. Social anxiety disorder. Lancet 2008, 371, 1115–1125.
14. Heimberg, R.G.; Becker, R.E. Cognitive-Behavioral Group Therapy for Social Phobia; Guilford Press: New York, NY, USA, 2002.
15. Schneier, F.R. Clinical practice. Social anxiety disorder. N. Engl. J. Med. 2006, 355, 1029–1036.
16. Leary, M.R.; Kowalski, R.M. Social anxiety. Guilford Press: New York, NY, USA, 1995.
17. Kessler, R.C.; Petukhova, M.; Sampson, N.A.; Zaslavsky, A.M.; Wittchen, H.U. Twelve-month and lifetime prevalence of DSM-IV disorders. Int. J. Methods Psychiatr. Res. 2012, 21, 169–184.
18. Abramowitz, J.S.; Taylor, S.; McKay, D. Obsessive-compulsive disorder. Lancet 2009, 374, 491 -499.
19. Fineberg, N.A.; Reghunandanan, S.; Brown, A.; Pampaloni, I. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int. J. Neuropsychopharmacol. 2013, 16, 557–579.
20. Stein, D.J.; Costa, D.L.; Lochner, C.; Miguel, E.C.; Reddy, Y.C.; Shavitt, R.G.; van den Heuvel, O.A.; Simpson, H.B. Obsessive-compulsive disorder. Nat. Rev. Dis. Primers 2019, 5, 52.
21. Ruscio, A.M.; Stein, D.J.; Chiu, W.T.; Kessler, R.C. The epidemiology of obsessive-compulsive disorder. Mol. Psychiatry 2010, 15, 53–63.
22. Yehuda, R. Post-traumatic stress disorder. N. Engl. J. Med. 2002, 346, 108–114.
23. Bremner, J.D. Neuroimaging studies in post-traumatic stress disorder. Curr. Psychiatry Rep. 2002, 4, 254–263.
24. Pitman, R.K.; Rasmusson, A.M.; Koenen, K.C.; Shin, L.M.; Orr, S.P.; Gilbertson, M.W.; Milad, M.R.; Liberzon, I. Biological studies of post-traumatic stress disorder. Nat. Rev. Neurosci. 2012, 13, 769–787.
25. Kendler, K.S. Major depression and generalized anxiety disorder. Same genes, different environments? Arch. Gen. Psychiatry 1992, 49, 716–722.
26. Hettema, J.M.; Neale, M.C.; Kendler, K.S. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am. J. Psychiatry 2001, 158, 1568–1578.
27. Smoller, J.W.; Block, S.R.; Young, M.M. Genetics of anxiety disorders: The complex road from DSM to DNA. Depress. Anxiety 2009, 26, 965–975.
28. Ressler, K.J.; Nemeroff, C.B. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress. Anxiety 2000, 12, 2–19.
29. Charney, D.S.; Drevets, W.C. Neurobiological basis of anxiety disorders. In Neuropsychopharmacology: The Fifth Generation of Progress; Davis, K.L., et al., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2002; pp. 901–930.
30. Insel, T.R.; Charney, D.S. Research on major depression: Strategies and priorities. JAMA 2003, 289, 3167–3168.
31. Beck, A.T.; Emery, G.; Greenberg, R.L. Anxiety Disorders and Phobias: A Cognitive Perspective; Basic Books: New York, NY, USA, 1985.
32. Clark, D.A.; Beck, A.T. Cognitive Therapy of Anxiety Disorders; Guilford Press: New York, NY, USA, 2010.
33. Barlow, D.H. Clinical Handbook of Psychological Disorders, 4th ed.; Guilford Press: New York, NY, USA, 2008.
34. Bienvenu, O.J.; Stein, M.B. Personality and anxiety disorders: A review. J. Pers. Disord. 2003, 17, 139–151.
35. McEwen, B.S. Protective and damaging effects of stress mediators. N. Engl. J. Med. 1998, 338, 171–179.
36. Sareen, J.; Afifi, T.O.; McMillan, K.A.; Asmundson, G.J. Relationship between household income and mental disorders. Arch. Gen. Psychiatry 2011, 68, 419–427.
37. Brewin, C.R.; Andrews, B.; Valentine, J.D. Meta-analysis of risk factors for PTSD in trauma-exposed adults. J. Consult. Clin. Psychol. 2000, 68, 748–766.
38. Strine, T.W.; Mokdad, A.H.; Dube, S.R.; Balluz, L.S.; Gonzalez, O.; Berry, J.T.; Manderscheid, R.; Kroenke, K. Depression and anxiety in the United States. Psychiatr. Serv. 2008, 59, 1383–1390.
39. Baxter, A.J.; Scott, K.M.; Vos, T.; Whiteford, H.A. Global prevalence of anxiety disorders. Psychol. Med. 2013, 43, 897–910.
40. Remes, O.; Brayne, C.; van der Linde, R.; Lafortune, L. A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain Behav. 2016, 6, e00497.
41. Lenze, E.J.; Wetherell, J.L. A lifespan view of anxiety disorders. Dialogues Clin. Neurosci. 2011, 13, 381–399.
42. World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates; WHO: Geneva, Switzerland, 2017.
43. Wittchen, H.U.; Jacobi, F. Size and burden of mental disorders in Europe. Eur. Neuropsychopharmacol. 2005, 15, 357–376.
44. Merikangas, K.R.; He, J.P.; Burstein, M.; Swanson, S.A.; Avenevoli, S.; Cui, L.; Benjet, C.; Georgiades, K.; Swendsen, J. Lifetime prevalence of mental disorders in U.S. adolescents. J. Am. Acad. Child Adolesc. Psychiatry 2010, 49, 980–989.
45. Beesdo, K.; Knappe, S.; Pine, D.S. Anxiety and anxiety disorders in children and adolescents. Psychiatr. Clin. North Am. 2009, 32, 483–524.
46. Bruce, S.E.; Yonkers, K.A.; Otto, M.W.; Eisen, J.L.; Weisberg, R.B.; Pagano, M.; Shea, M.T.; Keller, M.B. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder. Am. J. Psychiatry 2005, 162, 1179–1187.
47. McLean, C.P.; Asnaani, A.; Litz, B.T.; Hofmann, S.G. Gender differences in anxiety disorders. Psychiatr. Clin. North Am. 2011, 34, 465–474.
48. Sareen, J. Anxiety disorders and risk for suicidal ideation and suicide attempts. Arch. Gen. Psychiatry 2005, 62, 1249–1257.
49. Hofmann, S.G.; Asnaani, A.; Hinton, D.E. Cultural aspects in social anxiety and social anxiety disorder. Depress. Anxiety 2010, 27, 1117–1127. Brown, T.A.; Campbell, L.A.; Lehman, C.L.; Grisham, J.R.; Mancill, R.B. Current and lifetime comorbidity of anxiety and mood disorders. J. Abnorm. Psychol. 2001, 110, 585–599.
50. Kessler, R.C.; Chiu, W.T.; Demler, O.; Walters, E.E. Prevalence, severity, and comorbidity of DSM-IV disorders. Arch. Gen. Psychiatry 2005, 62, 617–627.
51. Pine, D.S. Research review: A neuroscience framework for pediatric anxiety disorders. J. Child Psychol. Psychiatry 2007, 48, 631–648.
52. Patel, V.; Saxena, S. Transforming lives, enhancing communities —innovations in global mental health. N. Engl. J. Med. 2014, 370, 498–501.
53. Martin, E.I.; Ressler, K.J.; Binder, E.; Nemeroff, C.B. The neurobiology of anxiety disorders: Brain imaging, genetics, and psychoneuroendocrinology. Psychiatr. Clin. North Am. 2009, 32, 549–575.
54. Shin, L.M.; Liberzon, I. The neurocircuitry of fear, stress, and anxiety disorders.
55. Neuropsychopharmacology 2010, 35, 169–191.
56. LeDoux, J.E. Emotion circuits in the brain. Annu. Rev. Neurosci. 2000, 23, 155–184.
57. Rauch, S.L.; Shin, L.M.; Wright, C.I. Neuroimaging studies of amygdala function in anxiety disorders. Ann. N. Y. Acad. Sci. 2003, 985, 389–410.
58. Etkin, A.; Wager, T.D. Functional neuroimaging of anxiety: A meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am. J. Psychiatry 2007, 164, 1476–1488.
59. Nutt, D.J.; Malizia, A.L. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br. J. Psychiatry 2001, 179, 390–396.
60. Möhler, H. The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology 2012, 62, 42–53.
61. Ressler, K.J.; Nemeroff, C.B. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol. Psychiatry 1999, 46, 1219–1233.
62. Smith, S.M.; Vale, W.W. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues Clin. Neurosci. 2006, 8, 383–395.
63. McEwen, B.S. Physiology and neurobiology of stress and adaptation. Physiol. Rev. 2007, 87, 873–904.
64. Kendler, K.S.; Gardner, C.O. Twin studies of adult psychiatric and substance dependence disorders. Arch. Gen. Psychiatry 1997, 54, 973–982.
65. Fox, N.A.; Henderson, H.A.; Marshall, P.J.; Nichols, K.E.; Ghera, M.M. Behavioral inhibition: Linking biology and behavior within a developmental framework. Annu. Rev. Psychol. 2005, 56, 235–262.
66. Heim, C.; Nemeroff, C.B. The role of childhood trauma in the neurobiology of mood and anxiety disorders. Biol. Psychiatry 2001, 49, 1023–1039.
67. Milad, M.R.; Quirk, G.J. Fear extinction as a model for translational neuroscience. Annu. Rev. Psychol. 2012, 63, 129–151.
68. Felger, J.C.; Lotrich, F.E. Inflammatory cytokines in depression and anxiety. Neuroscience 2013, 246, 199–229.
69. Tyrer, P. Anxiety disorders: Clinical features and diagnosis. Medicine 2006, 34, 393–395.
70. Stein, M.B.; Sareen, J. Clinical practice: Generalized Anxiety Disorder and Panic Disorder. N. Engl. J. Med. 2015, 373, 2059–2068.
71. Hoffman, D.L.; Dukes, E.M.; Wittchen, H.U. Human and economic burden of generalized anxiety disorder. Depress. Anxiety 2008, 25, 72–90.
72. Kaplan, H.I.; Sadock, B.J. Synopsis of Psychiatry, 10th ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2007.
73. Gelder, M.; Mayou, R.; Cowen, P. Shorter Oxford Textbook of Psychiatry, 5th ed.; Oxford University Press: Oxford, UK, 2006.
74. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; APA: Washington, DC, USA, 2013.
75. Beck, A.T.; Clark, D.A. An information processing model of anxiety. Behav. Res. Ther. 1997, 35, 49–58.
76. Eysenck, M.W.; Derakshan, N.; Santos, R.; Calvo, M.G. Anxiety and cognitive performance. Emotion 2007, 7, 336–353.
77. Mathews, A.; MacLeod, C. Cognitive vulnerability to emotional disorders. Annu. Rev. Clin. Psychol. 2005, 1, 167–195.
78. Clark, D.M.; Beck, A.T. Cognitive Therapy of Anxiety Disorders; Guilford Press: New York, NY, USA, 2010.
79. Rapee, R.M.; Heimberg, R.G. A cognitive-behavioral model of anxiety in social phobia. Behav. Res. Ther. 1997, 35, 741–756.
80. Antony, M.M.; Swinson, R.P. Phobic Disorders and Panic in Adults; American Psychological Association: Washington, DC, USA, 2000.
81. Salkovskis, P.M. Understanding and treating obsessive-compulsive disorder. Behav. Res. Ther. 1999, 37, S29–S52.
82. Friedman, B.H. Feelings and the body: The Jamesian perspective on autonomic specificity of emotion. Biol. Psychol. 2010, 84, 383–393.
83. Hoehn-Saric, R.; McLeod, D.R. Anxiety and arousal: Physiological changes and their perception. J. Affect. Disord. 2000, 61, 217–224.
84. Craske, M.G.; Barlow, D.H. Panic disorder and agoraphobia. In Clinical Handbook of Psychological Disorders; Guilford Press: New York, NY, USA, 2008; pp. 1–64.
85. Fleet, R.P.; Dupuis, G.; Marchand, A.; Burelle, D.; Beitman, B.D. Panic disorder in emergency department chest pain patients. Psychosomatics 1996, 37, 330–335.
86. Sadock, B.J.; Sadock, V.A.; Ruiz, P. Kaplan and Sadock’s Comprehensive Textbook of Psychiatry, 9th ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2009.
87. Allgulander, C. Generalized anxiety disorder: What are we missing? Eur. Neuropsychopharmacol. 2006, 16, S101–S108.
88. Gorman, J.M.; Kent, J.M.; Sullivan, G.M.; Coplan, J.D. Neuroanatomical hypothesis of panic disorder. Am. J. Psychiatry 2000, 157, 493–505.
89. Blanco, C.; Schneier, F.R.; Schmidt, A.; Blanco-Jerez, C.; Marshall, R.D.; Sánchez-Lacay, A.; Liebowitz, M.R. Pharmacological treatment of social anxiety disorder. Biol. Psychiatry 2003, 54, 1079–1088.
90. Fredrikson, M.; Annas, P.; Fischer, H.; Wik, G. Gender and age differences in the prevalence of specific fears and phobias. Behav. Res. Ther. 1996, 34, 33–39.
91. Nemeroff, C.B.; Bremner, J.D.; Foa, E.B.; Mayberg, H.S.; North, C.S.; Stein, M.B. Posttraumatic stress disorder: A state-of-the-science review. J. Psychiatr. Res. 2006, 40, 1–21.
92. Greenberg, P.E.; Sisitsky, T.; Kessler, R.C.; Finkelstein, S.N.; Berndt, E.R.; Davidson, J.R.; Ballenger, J.C.; Fyer, A.J. The economic burden of anxiety disorders in the 1990s. J. Clin. Psychiatry 1999, 60, 427–435.
93. Olatunji, B.O.; Cisler, J.M.; Tolin, D.F. Quality of life in the anxiety disorders. Clin. Psychol. Rev. 2007, 27, 572–581.
94. Roy-Byrne, P.; Wagner, A. Primary care perspectives on generalized anxiety disorder. J. Clin. Psychiatry 2004, 65, 20–26.
95. First, M.B.; Tasman, A. Clinical Guide to the Diagnosis and Treatment of Mental Disorders; Wiley: Hoboken, NJ, USA, 2006.
96. Tyrer, P.; Baldwin, D. Generalized anxiety disorder. Lancet 2006, 368, 2156–2166.
97. Gelder, M.G. Psychological assessment and diagnosis in psychiatry. Oxford Textbook of Psychiatry; Oxford University Press: Oxford, UK, 2008.
98. Sadock, B.J.; Sadock, V.A. Kaplan and Sadock’s Synopsis of Psychiatry, 11th ed.; Wolters Kluwer: Philadelphia, PA, USA, 2015.
99. Ballenger, J.C. Clinical guidelines for establishing remission in patients with depression and anxiety. J. Clin. Psychiatry 1999, 60, 29–34.
100. Shear, M.K.; Belnap, B.H.; Mazumdar, S.; Houck, P.; Rollman, B.L. Generalized anxiety disorder severity scale (GADSS): A preliminary validation study. Depressed. Anxiety 2006, 23, 77–82.
101. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; APA: Arlington, VA, USA, 2013.
102. World Health Organization. ICD-11 Classification of Mental and Behavioural Disorders; WHO: Geneva, Switzerland, 2019.
103. Craske, M.G.; Rauch, S.L.; Ursano, R.; Prenoveau, J.; Pine, D.S.; Zinbarg, R.E. What is an anxiety disorder? Depress. Anxiety 2009, 26, 1066–1085.
104. Trzepacz, P.T.; Baker, R.W. The Psychiatric Mental Status Examination; Oxford University Press: New York, NY, USA, 1993.
105. Sims, A. Symptoms in the Mind: An Introduction to Descriptive Psychopathology, 4th ed.; Saunders Elsevier: Edinburgh, UK, 2008.
106. Fish, F.J. Fish’s Clinical Psychopathology, 3rd ed.; Wright: Bristol, UK, 1997.
107. Hamilton, M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 1959, 32, 50–55.
108. Spitzer, R.L.; Kroenke, K.; Williams, J.B.; Löwe, B. A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch. Intern. Med. 2006, 166, 1092–1097.
109. Beck, A.T.; Epstein, N.; Brown, G.; Steer, R.A. An inventory for measuring clinical anxiety. J. Consult. Clin. Psychol. 1988, 56, 893–897.
110. Katon, W.; Roy-Byrne, P.P. Panic disorder and medically unexplained symptoms. Prim. Care Companion J. Clin. Psychiatry 2007, 9, 30–37.
111. Barsky, A.J.; Wyshak, G.; Klerman, G.L. The somatosensory amplification scale and its relationship to hypochondriasis. J. Psychiatr. Res. 1990, 24, 323–334.
112. Hales, R.E.; Yudofsky, S.C.; Gabbard, G.O. The American Psychiatric Publishing Textbook of Psychiatry, 5th ed.; APA Publishing: Washington, DC, USA, 2008.
113. Baldwin, D.S.; Anderson, I.M.; Nutt, D.J.; Bandelow, B.; Bond, A.; Davidson, J.R.; den Boer, J.A.; Fineberg, N.A.; Knapp, M.; Scott, J.; Wittchen, H.U. Evidence-based guidelines for the pharmacological treatment of anxiety disorders. J. Psychopharmacol. 2005, 19, 567–596.
114. Hirschfeld, R.M. The comorbidity of major depression and anxiety disorders. Prim. Care Companion J. Clin. Psychiatry 2001, 3, 244–254.
115. Schatzberg, A.F.; Nemeroff, C.B. The American Psychiatric Publishing Textbook of Psychopharmacology, 4th ed.; APA Publishing: Washington, DC, USA, 2009.
116. Andrews, G.; Issakidis, C.; Sanderson, K.; Corry, J.; Lapsley, H. Utilising survey data to inform public policy. Aust. N. Z. J. Psychiatry 2004, 38, 812–818.
117. Kroenke, K.; Spitzer, R.L.; Williams, J.B.; Monahan, P.O.; Löwe, B. Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection. Ann. Intern. Med. 2007, 146, 317–325.
118. Wittchen, H.U.; Jacobi, F.; Rehm, J.; Gustavsson, A.; Svensson, M.; Jönsson, B.; Olesen, J.; Allgulander, C.; Alonso, J.; Faravelli, C.; et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 2011, 21, 655–679.
119. Stevens, J.F.; Page, J.E. Xanthohumol and related prenylflavonoids from hops (Humulus lupulus L.) and beer: To your good health! Phytochemistry 2004, 65, 1317–1330.
120. Karabín, M.; Hudcová, T.; Jelínek, L.; Dostálek, P. Biologically active compounds from hops and prospects for their use. Compr. Rev. Food Sci. Food Saf. 2016, 15, 542–567.
121. Franco, L.; Sanchez, C.; Bravo, R.; Rodriguez, A.; Barriga, C.; Juanez, J.C. The sedative effects of hops (Humulus lupulus), a component of beer, on the activity/rest rhythm. Acta Physiol. Hung. 2012, 99, 133–139.
122. Fidan, H.; Stefanova, G.; Kostova, I.; Stankov, S.; Damyanova, S.; Stoyanova, A.; Zheljazkov, V.D. Chemical composition and antimicrobial activity of Laurus nobilis L. essential oils from Bulgaria. Molecules 2019, 24, 804.
123. Chahal, K.K.; Kaur, M.; Bhardwaj, U.; Singla, N.; Kaur, A. A review on chemistry and biological activities of Laurus nobilis L. essential oil. J. Pharmacogn. Phytochem. 2017, 6, 1153–1161.
124. Sayyah, M.; Saroukhani, G.; Peirovi, A.; Kamalinejad, M. Analgesic and anti-inflammatory activity of the leaf essential oil of Laurus nobilis Linn. Phytother. Res. 2003, 17, 733–736.
125. Pramod, K.; Ansari, S.H.; Ali, J. Eugenol: A natural compound with versatile pharmacological actions. Nat. Prod. Commun. 2010, 5, 1999–2006.
126. Verma, R.S.; Rahman, L.U.; Chanotiya, C.S.; Verma, R.K.; Chauhan, A.; Yadav, A.; Yadav, A.K. Essential oil composition of Lavandula angustifolia Mill. cultivated in the mid hills of Uttarakhand, India. J. Serb. Chem. Soc. 2010, 75, 343–348.
127. Hritcu, L.; Cioanca, O.; Hancianu, M. Effects of lavender oil inhalation on improving scopolamine-induced spatial memory impairment in laboratory rats. Phytomedicine 2012, 19, 529–534.
128. Lim, W.C.; Seo, J.M.; Lee, C.I.; Pyo, H.B.; Lee, B.C. Stimulative and sedative effects of essential oils upon inhalation in mice. Arch. Pharm. Res. 2005, 28, 770–774.
129. Woelk, H.; Schlafke, S. A multi-center, double-blind, randomized study of the lavender oil preparation Silexan in comparison to lorazepam for generalized anxiety disorder. Phytomedicine 2010, 17, 94–99.
130. Bradley, B.F.; Brown, S.L.; Chu, S.; Lea, R.W. Effects of orally administered lavender essential oil on responses to anxiety-provoking film clips. Hum. Psychopharmacol. 2009, 24, 319–330.
131. Moeini, M.; Khadibi, M.; Bekhradi, R.; Mahmoudian, S.A.; Nazari, F. Effect of aromatherapy on the quality of sleep in ischemic heart disease patients hospitalized in intensive care units. Iran. J. Nurs. Midwifery Res. 2010, 15, 234–239.
132. Chien, L.W.; Cheng, S.L.; Liu, C.F. The effect of lavender aromatherapy on autonomic nervous system in midlife women with insomnia. Evid.-Based Complement. Altern. Med. 2012, 2012, 740813.
133. Lewith, G.T.; Godfrey, A.D.; Prescott, P. A single-blinded, randomized pilot study evaluating the aroma of Lavandula angustifolia as a treatment for mild insomnia. J. Altern. Complement. Med. 2005, 11, 631–637.
134. Gasparetto, J.C.; Martins, C.A.; Hayashi, S.S.; Otuky, M.F.; Pontarolo, R. Ethnobotanical and scientific aspects of Malva sylvestris L.: A millennial herbal medicine. J. Pharm. Pharmacol. 2012, 64, 172–189.
135. Barros, L.; Carvalho, A.M.; Ferreira, I.C. Leaves, flowers, immature fruits and leafy flowered stems of Malva sylvestris: A comparative study of the nutraceutical potential and composition. Food Chem. Toxicol. 2010, 48, 1466–1472.
136. Billeter, M.; Meier, B.; Sticher, O. 8-Hydroxyflavonoid glucuronides from Malva sylvestris. Phytochemistry 1991, 30, 987–990.
137. Farina, A.; Doldo, A.; Cotichini, V.; Rajevic, M.; Quaglia, M.G.; Mulinacci, N.; Vincieri, F.F. HPTLC and reflectance mode densitometry of anthocyanins in Malva sylvestris L. J. Pharm. Biomed. Anal. 1995, 14, 203–211.
138. Takeda, K.; Enoki, S.; Harborne, J.B.; Eagles, J. Malonated anthocyanins in Malvaceae: Malonylmalvin from Malva sylvestris. Phytochemistry 1989, 28, 499–500.
139. Daniela, A.; Pichichero, E.; Canuti, L.; Cicconi, R.; Karou, D.; D’Arcangelo, G.; Canini, A. Identification of phenolic compounds from medicinal and melliferous plants and their cytotoxic activity in cancer cells. Caryologia 2007, 60, 90–95.
140. Cutillo, F.; D’Abrosca, B.; Dellagreca, M.; Fiorentino, A.; Zarrelli, A. Terpenoids and phenol derivatives from Malva sylvestris. Phytochemistry 2006, 67, 481–485.
141. Mann, C.; Staba, E.J. The chemistry, pharmacology, and commercial formulations of chamomile. J. Herbs Spices Med. Plants 1986, 1, 235–280.
142. Stanojevic, L.P.; Marjanovic-Balaban, Z.R.; Kalaba, V.D.; Stanojevic, J.S.; Cvetkovic, D.J. Chemical composition, antioxidant and antimicrobial activity of chamomile flowers essential oil (Matricaria chamomilla L.). J. Essent. Oil Bear. Plants 2016, 19, 2017–2028.
143. Fonseca, F.N.; Tavares, M.F.; Horvath, C. Capillary electrochromatography of selected phenolic compounds of Chamomilla recutita. J. Chromatogr. A 2007, 1154, 390–399.
144. Jenabi, E.; Ebrahimzadeh, S. The effect of Matricaria chamomilla tea on primary dysmenorrheal. J. Med. Plants 2009, 8, 39–42.
145. Niazi, A.; Moradi, M. The effect of chamomile on pain and menstrual bleeding in primary dysmenorrhea: A systematic review. Int. J. Community Based Nurs. Midwifery 2021, 9, 174–186.
146. Sharafzadeh, S.; Alizadeh, O. German and Roman chamomile. J. Appl. Pharm. Sci. 2011, 1, 1–5.
147. Singh, O.; Khanam, Z.; Misra, N.; Srivastava, M.K. Chamomile (Matricaria chamomilla L.): An overview. Pharmacogn. Rev. 2011, 5, 82–95.
148. Cemek, M.; Kaga, S.; Simsek, N.; Buyukokuroglu, M.E.; Konuk, M. Antihyperglycemic and antioxidative potential of Matricaria chamomilla L. in streptozotocin-induced diabetic rats. J. Nat. Med. 2008, 62, 284–293.
149. Ranjbar, A.; Mohsenzadeh, F.; Chehregani, A.; Khajavi, F.; Zijoud, S.M.; Ghasemi, H. Ameliorative effect of Matricaria chamomilla L. on paraquat-induced oxidative damage in lung rats. Pharmacogn. Res. 2014, 6, 199–203.
150. Srivastava, J.K.; Gupta, S. Antiproliferative and apoptotic effects of chamomile extract in various human cancer cells. J. Agric. Food Chem. 2007, 55, 9470–9478.
151. Avallone R, Zanoli P, Corsi L, Cannazza G, Baraldi M. Benzodiazepine-like compounds and GABA in flower head of Matricaria chamomilla. Phytother Res. 1996;10:177–179.
152. Melissa officinalis Miraj S, Azizi N, Kiani S. A review of chemical components and pharmacological effects of Melissa officinalis L. Der Pharm Lett. 2016;8:229–237.
153. Abdellatif F, Boudjella H, Zitouni A, Hassani A. Chemical composition and antimicrobial activity of the essential oil from leaves of Algerian Melissa officinalis L. EXCLI J. 2014;13:772–781.
154. Hancianu M, Aprotosoaie AC, Gille E, Poiata A, Tuchilus C, Spac A, Stanescu U. Chemical composition and in vitro antimicrobial activity of essential oil of Melissa officinalis L. from Romania. Rev Med Chir Soc Med Nat Iasi. 2008;112:843–847.
155. Taherpour AA, Maroofi H, Rafie Z, Larijani K. Chemical composition analysis of the essential oil of Melissa officinalis L. from Kurdistan, Iran. Nat Prod Res. 2012;26:152–160.
156. Tittel G, Wagner H, Bos R. Chemical composition of the essential oil from melissa. Planta Med. 1982;46:91–98.
157. Adinee J, Piri K, Karami O. Essential oil component in flower of lemon balm (Melissa officinalis L.). Am J Biochem Biotechnol. 2008;4:277–278.
158. Ibarra A, Feuillere N, Roller M, Lesburgere E, Beracochea D. Effects of chronic administration of Melissa officinalis L. extract on anxiety-like reactivity and circadian activities in mice. Phytomedicine. 2010;17:397–403.
159. Ocimum basilicum Al Abbasy DW, Pathare N, Al-Sabahi JN, Khan SA. Chemical composition and antibacterial activity of essential oil isolated from Omani basil (Ocimum basilicum Linn.). Asian Pac J Trop Dis. 2015;5:645–649.
160. Li H, Ge Y, Luo Z, Zhou Y, Zhang X, Zhang J, Fu Q. Evaluation of the chemical composition, antioxidant and anti-inflammatory activities of sweet basil essential oil. J Food Sci Technol. 2017;54:1882–1890.
161. McCance KR, Flanigan PM, Quick MM, Niemeyer ED. Influence of plant maturity on anthocyanin concentrations and antioxidant properties of purple basil cultivars. J Food Compos Anal. 2016;53:30–39.
162. Dhama K, Sharun K, Gugjoo MB, Tiwari R, Alagawany M, Yatoo MI, et al. A comprehensive review on chemical profile and pharmacological activities of Ocimum basilicum. Food Rev Int. 2021;1–29.
163. Tran TH, Nguyen HHH, Nguyen DC, Nguyen TQ, Tan H, Nhan LTH, et al. Optimization of microwave-assisted extraction of essential oil from Vietnamese basil (Ocimum basilicum L.). Processes. 2018;6:206.
164. Ibrahim RYM, Mansour SM, Elkady WM. Phytochemical profile and protective effect of Ocimum basilicum aqueous extract. J Pharm Pharmacol. 2020;72:101–110.
165. Askari VR, Baradaran Rahimi V, Ghorbani A, Rakhshandeh H. Hypnotic effect of Ocimum basilicum on pentobarbital-induced sleep in mice. Iran Red Crescent Med J. 2016;18:e24261.
166. Rosmarinus officinalis Andrade JM, Faustino C, Garcia C, Ladeiras D, Reis CP, Rijo P. Rosmarinus officinalis L.: An update review of its phytochemistry and biological activity. Future Sci OA. 2018;4:FSO283.
167. Ulbricht C, Abrams TR, Brigham A, Ceurvels J, Clubb J, Curtiss W, et al. An evidence-based systematic review of rosemary (Rosmarinus officinalis). J Diet Suppl. 2010;7:351–413.
168. Diego MA, Jones NA, Field T, Hernandez-Reif M, Schanberg S, Kuhn C, et al. Aromatherapy positively affects mood and alertness. Int J Neurosci. 1998;96:217–224.
169. Park MK, Lee ES. The effect of aroma inhalation method on stress responses of nursing students. J Korean Acad Nurs. 2004;34:344–351.
170. Ferlemi AV, Katsikoudi A, Kontogianni VG, Kellici TF, Iatrou G, Lamari FN, et al. Rosemary tea consumption results in anxiolytic-and antidepressant-like behavior in mice. Chem Biol Interact. 2015;237:47–57.
171. Noori Ahmad Abadi M, Mortazavi M, Kalani N, Marzouni HZ, Kooti W, Ali-Akbari S. Effect of hydroalcoholic extract of Rosmarinus officinalis leaf on anxiety in mice. J Evid Based Complementary Altern Med. 2016;21:NP85–NP90.
172. Daher CF, Kashour BM. Rosmarinus officinalis leaves water extract: A possible anti-inflammatory and anti-ulcerogenic remedy. Planta Med. 2008;74:PA203.
173. EMA. Assessment Report on Rosmarinus officinalis L. Aetheroleum and Rosmarinus officinalis L. Folium. Amsterdam: European Medicines Agency; 2009.
174. McCaffrey R, Thomas DJ, Kinzelman AO. The effects of lavender and rosemary essential oils on test-taking anxiety among graduate nursing students. Holist Nurs Pract. 2009;23:88–93.
175. Solhi H, Salehi B, Alimoradian A, Pazouki S, Taghizadeh M, Saleh AM, Kazemifar AM. Beneficial effects of Rosmarinus officinalis for treatment of opium withdrawal syndrome during addiction treatment programs: A clinical trial. Addict Health. 2013;5:90–94.
176. Nematolahi P, Mehrabani M, Karami-Mohajeri S, Dabaghzadeh F. Effects of Rosmarinus officinalis L. on memory performance, anxiety, depression, and sleep quality in university students: A randomized clinical trial. Complement Ther Clin Pract. 2018;30:24–28.
177. Achour M, Ben Salem I, Ferdousi F, Nouira M, Ben Fredj M, Mtiraoui A, et al. Rosemary tea consumption alters peripheral anxiety and depression biomarkers: A pilot study in healthy volunteers. J Am Coll Nutr. 2021;1–10.
178. Tilia cordata Karioti A, Chiarabini L, Alachkar A, Chehna MF, Vincieri FF, Bilia AR. HPLC–DAD and HPLC–ESI-MS analyses of Tiliae flos and its preparations. J Pharm Biomed Anal. 2014;100:205–214.
179. Symma N, Sendker J, Petereit F, Hensel A. Multistep analysis of Diol-LC-ESI-HRMS data reveals proanthocyanidin composition of complex plant extracts. J Agric Food Chem. 2020;68:8040–8049.
180. Toker G, Baser KHC, Kürkçüoglu M, Özek T. The composition of essential oils from Tilia species growing in Turkey. J Essent Oil Res. 1999;11:369–374.
181. Symma N, Butergerds M, Sendker J, Petereit F, Hake A, Dufer M, et al. Novel alkaloids from Tilia platyphyllos and Tilia cordata flowers. Planta Med. 2021;87:686–700.
182. EMA. Community Herbal Monograph on Tilia cordata Miller, Tilia platyphyllos Scop., Tilia x vulgaris Heyne or their mixtures, flos. Amsterdam: European Medicines Agency; 2011.
183. Aguirre-Hernandez E, Martinez AL, Gonzalez-Trujano ME, Moreno J, Vibrans H, Soto-Hernandez M. Pharmacological evaluation of the anxiolytic and sedative effects of Tilia americana var. mexicana in mice. J Ethnopharmacol. 2007;109:140–145.
184. Cotrim MD, Figueiredo IV, Cavadas C, Cunha A, Caramona MM, Macedo TRA. Pharmacological properties of Tilia europaea aqueous extract: Screening anxiolytic/sedative activity in mice. Arq Patol Geral Anat Patol Univ Coimbra. 2005;31:23–25.
185. Herrera-Ruiz M, Roman-Ramos R, Zamilpa A, Tortoriello J, Jimenez-Ferrer JE. Flavonoids from Tilia americana with anxiolytic activity in plus-maze test. J Ethnopharmacol. 2008;118:312–317.
186. Negri G, Santi DD, Tabach R. Flavonol glycosides found in hydroethanolic extracts from Tilia cordata. Rev Bras Plantas Med. 2013;15:217–224.
187. Pérez-Ortega G, Guevara-Fefer P, Chávez M, Herrera J, Martínez A, Martínez AL, et al. Sedative and anxiolytic efficacy of Tilia americana var. mexicana inflorescences. J Ethnopharmacol. 2008;116:461–468.
188. Valeriana officinalis Jiang X, Zhang JC, Liu YW, Fang Y. Studies on chemical constituents of Valeriana officinalis. J Chin Med Mater. 2007;30:1391–1393.
189. Janot MM, Guilhem J, Contz O, Venera G, Cionga E. Contribution to the study of valerian alkaloids (Valeriana officinalis L.). Ann Pharm Fr. 1979;37:413–420.
190. Torssell K, Wahlberg K. Isolation, structure and synthesis of alkaloids from Valeriana officinalis L. Acta Chem Scand. 1967;21:53–62.
191. Pato?ka J, Jakl J. Biomedically relevant chemical constituents of Valeriana officinalis. J Appl Biomed. 2010;8:11–18.
192. Michael T, Murray ND. Valeriana officinalis (Valerian). In: Textbook of Natural Medicine. 5th ed. Amsterdam: Elsevier; 2020. pp. 902–905.
193. Bos R, Woerdenbag HJ, Pras N. Determination of valepotriates. J Chromatogr A. 2002;967:131–146.
194. Nandhini S, Narayanan KB, Ilango K. Valeriana officinalis: A review of its traditional uses, phytochemistry and pharmacology. Asian J Pharm Clin Res. 2018;11:36–41.
195. Trauner G, Khom S, Baburin I, Benedek B, Hering S, Kopp B. Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acid. Planta Med. 2008;74:19–24.
196. Murphy K, Kubin ZJ, Shepherd JN, Ettinger RH. Valeriana officinalis root extracts have potent anxiolytic effects in laboratory rats. Phytomedicine. 2010;17:674–678.
197. Bent S, Padula A, Moore D, Patterson M, Mehling W. Valerian for sleep: A systematic review and meta-analysis. Am J Med. 2006;119:1005–1012.
198. Fernandez-San-Martin MI, Masa-Font R, Palacios-Soler L, Sancho-Gomez P, Calbo-Caldentey C, Flores-Mateo G. Effectiveness of valerian on insomnia: A meta-analysis of randomized placebo-controlled trials. Sleep Med. 2010;11:505–511.
199. Shinjyo N, Waddell G, Green J. Valerian root in treating sleep problems and associated disorders—A systematic review and meta-analysis. J Evid Based Integr Med. 2020;25:2515690X20967323.
200. Stevinson C, Ernst E. Valerian for insomnia: A systematic review of randomized clinical trials. Sleep Med. 2000;1:91–99.
201. Taibi DM, Landis CA, Petry H, Vitiello MV. A systematic review of valerian as a sleep aid: Safe but not effective. Sleep Med Rev. 2007;11:209–230.
202. Heinrich M, Kufer J, Leonti M, Pardo-de-Santayana M. Ethnobotany and ethnopharmacology—Interdisciplin ary links with the historical sciences. J Ethnopharmacol. 2006;107:157–160.
203. Ulbricht C, Abrams TR, Brigham A, Ceurvels J, Clubb J, Curtiss W, et al. Evidence-based review of herbal medicines in mental health. J Diet Suppl. 2010;7:351–413.
204. Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93–107.
205. Dhama K, Sharun K, Gugjoo MB, Tiwari R, Alagawany M, Yatoo MI, et al. Herbal medicines and phytochemicals: Future perspectives in neuropsychiatric disorders. Food Rev Int. 2021;1–29.
206. Shinjyo N, Waddell G, Green J. Herbal medicine in sleep and anxiety disorders: Future clinical perspectives. J Evid Based Integr Med. 2020;25:2515690X20967323.
207. EMA. Guidelines on quality of herbal medicinal products. Amsterdam: European Medicines Agency; 2016.
208. Andrade JM, Faustino C, Garcia C, Ladeiras D, Reis CP, Rijo P. Novel delivery systems and phytochemical advances in herbal medicines. Future Sci OA. 2018;4:FSO283.
209. World Health Organization. WHO Traditional Medicine Strategy 2014–2023. Geneva: WHO; 2013.